Daiwa Securities Group Inc. Sells 1,081 Shares of Waters Co. (NYSE:WAT)

Daiwa Securities Group Inc. lowered its stake in shares of Waters Co. (NYSE:WAT) by 7.4% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 13,523 shares of the medical instruments supplier’s stock after selling 1,081 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Waters were worth $3,019,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of WAT. Invesco Ltd. boosted its position in Waters by 20.3% during the second quarter. Invesco Ltd. now owns 775,740 shares of the medical instruments supplier’s stock worth $166,971,000 after purchasing an additional 130,671 shares during the period. Mackenzie Financial Corp boosted its position in Waters by 252.8% during the second quarter. Mackenzie Financial Corp now owns 638,075 shares of the medical instruments supplier’s stock worth $137,339,000 after purchasing an additional 457,218 shares during the period. Mawer Investment Management Ltd. boosted its position in Waters by 7.1% during the second quarter. Mawer Investment Management Ltd. now owns 532,219 shares of the medical instruments supplier’s stock worth $114,531,000 after purchasing an additional 35,506 shares during the period. UBS Asset Management Americas Inc. boosted its position in Waters by 2.3% during the second quarter. UBS Asset Management Americas Inc. now owns 472,001 shares of the medical instruments supplier’s stock worth $101,593,000 after purchasing an additional 10,728 shares during the period. Finally, Jensen Investment Management Inc. boosted its position in Waters by 1.4% during the second quarter. Jensen Investment Management Inc. now owns 446,637 shares of the medical instruments supplier’s stock worth $96,134,000 after purchasing an additional 5,976 shares during the period. Institutional investors own 95.15% of the company’s stock.

WAT stock opened at $210.08 on Friday. The firm has a 50 day moving average of $218.07 and a 200-day moving average of $214.06. The company has a current ratio of 2.25, a quick ratio of 1.63 and a debt-to-equity ratio of 11.40. Waters Co. has a 12 month low of $173.41 and a 12 month high of $255.21. The firm has a market capitalization of $13.76 billion, a P/E ratio of 25.34, a price-to-earnings-growth ratio of 2.54 and a beta of 1.04.

Waters (NYSE:WAT) last released its quarterly earnings data on Tuesday, October 29th. The medical instruments supplier reported $2.13 EPS for the quarter, meeting analysts’ consensus estimates of $2.13. Waters had a net margin of 23.98% and a return on equity of 77.73%. The company had revenue of $577.28 million during the quarter, compared to analyst estimates of $588.35 million. During the same period last year, the business earned $1.92 earnings per share. Waters’s revenue was down .1% compared to the same quarter last year. Sell-side analysts predict that Waters Co. will post 8.84 EPS for the current year.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

In other news, SVP Elizabeth B. Rae sold 29,326 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $213.12, for a total value of $6,249,957.12. Following the completion of the transaction, the senior vice president now directly owns 23,932 shares in the company, valued at $5,100,387.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Laurie H. M.D. Glimcher sold 2,200 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $214.64, for a total transaction of $472,208.00. Following the completion of the transaction, the director now owns 3,600 shares of the company’s stock, valued at $772,704. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by company insiders.

A number of equities analysts have weighed in on WAT shares. Barclays lowered shares of Waters from an “equal weight” rating to an “underweight” rating and cut their target price for the stock from $210.00 to $195.00 in a research report on Wednesday, October 9th. Bank of America lowered shares of Waters from a “neutral” rating to an “underperform” rating in a research report on Tuesday, July 16th. Needham & Company LLC reiterated a “hold” rating on shares of Waters in a research report on Tuesday, October 29th. TheStreet lowered shares of Waters from a “b” rating to a “c+” rating in a research report on Tuesday, October 29th. Finally, Robert W. Baird increased their target price on shares of Waters from $208.00 to $217.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. Six investment analysts have rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the stock. Waters has a consensus rating of “Hold” and a consensus target price of $209.60.

About Waters

Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.

Featured Article: Risk Tolerance and Your Investment Decisions

Want to see what other hedge funds are holding WAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Waters Co. (NYSE:WAT).

Institutional Ownership by Quarter for Waters (NYSE:WAT)

Leave a Reply

Your email address will not be published. Required fields are marked *

*